News articles about Orexigen Therapeutics (NASDAQ:OREX) have been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a service of Accern, rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Orexigen Therapeutics earned a daily sentiment score of 0.14 on AlphaOne’s scale. AlphaOne also gave media stories about the biopharmaceutical company an impact score of 93 out of 100, meaning that recent news coverage is extremely likely to have an effect on the stock’s share price in the next several days.
These are some of the news articles that may have effected AlphaOne’s scoring:
- Advertising Law – June 2017 #3 (jdsupra.com)
- Orexigen Therapeutics, Inc. : Edison Issues Outlook on Orexigen Therapeutics (OREX) (4-traders.com)
- Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound? – Nasdaq (nasdaq.com)
- Orexigen Therapeutics, Inc. (OREX) noted a price change of 0.35% and AC Immune SA (ACIU) closes with a move of … – Stocks Gallery (stocksgallery.com)
Separately, ValuEngine lowered shares of Orexigen Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
Orexigen Therapeutics (NASDAQ:OREX) traded down 1.76% during mid-day trading on Friday, hitting $2.79. 51,182 shares of the stock traded hands. The company’s market cap is $42.48 million. Orexigen Therapeutics has a 12 month low of $1.65 and a 12 month high of $5.70. The stock’s 50 day moving average is $3.09 and its 200-day moving average is $3.23.
Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($4.67) EPS for the quarter, missing analysts’ consensus estimates of ($2.60) by $2.07. Orexigen Therapeutics had a negative return on equity of 580.50% and a negative net margin of 149.02%. The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $20 million. During the same quarter last year, the firm posted ($1.54) earnings per share. The firm’s quarterly revenue was up 282.0% compared to the same quarter last year. On average, equities research analysts anticipate that Orexigen Therapeutics will post ($11.47) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/06/16/orexigen-therapeutics-orex-given-news-sentiment-rating-of-0-14-updated-updated.html.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Receive News & Ratings for Orexigen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.